With a license from Nagoya University and Shinshu University, J-TEC plans to develop, manufacture and market its own CART for CD19 positive acute lymphoblastic leukemia (ALL). The CART developed uses the piggyBac transposon method, a non-viral vector which introduces the CAR gene into T cells. Because the piggyBac transposon method does not use a virus, manufacturing cost may be reduced because existing facilities can be used.

J-TEC news release, June 21, 2018